When regulation stops being a cost and starts becoming a competitive advantage

For years, regulatory compliance in sectors like medtech or digital health was handled internally or outsourced to consulting firms. What is changing in 2026 is the underlying logic itself: compliance is becoming software, infrastructure, and ultimately, a product.

In February 2026, three European companies closed funding rounds around a shared thesis: automating regulatory compliance in regulated sectors is no longer a secondary service it is the core product.

• Biorce (Barcelona) raised $52.5M in a Series A round to scale its AI platform for clinical trial design.
• Flinn.ai (Vienna) secured $20M to automate audits and quality processes in medtech and pharma.
• Klaris (London) closed a $1M Pre medical device manufacturers. seed round to build document review tools for medical device manufacturers.

Three stages, three geographies, one signal.

A regulatory timeline that turns compliance into operational urgency

The European Medical Device Regulation (MDR) has been increasing pressure on manufacturers and startups for years, but timelines are now becoming concrete.

EUDAMED modules — the European database for medical device registration and tracking — will become mandatory from May 28, 2026. High by December 2027; medium- and low– risk devices must be certified risk devices by December 2028. Each milestone carries a direct cost: according to MedTech Europe, a certification cycle can reach several million euros, with maintenance costs exceeding initial costs over a fiveyear period.

At the same time, the AI Act introduces additional requirements for AI systems used in diagnostics or clinical decisionmaking. In 2025, the European Commission published MDCG 20256, explicitly regulating the interaction between MDR and the AI Act.

In practice, any digital health startup aiming to operate in Europe must comply with both MDR and the AI Act simultaneously. The combination increases certification timelines, documentation requirements, and operational costs in a cumulative way. That pres precisely the problem that compliance as a product platforms aim to solve.

Why capital is flowing now

There are two reasons behind the timing – and it’s worth separating them.

The first is technological. Language models applied to regulatory documentation have matured enough to support products with demonstrable value. Ketryx, which raised $39M in a Series B round in 2025, automates validation, traceability, and documentation re ady for FDA and MDR requirements. This is not a search assistant — it is an operational layer replacing manual processes with high cost and high error rates.

The second reason is structural. Medtech startups aiming to commercialize in Europe do not have a choice: the cost of noncompliance is exclusion from the market. In that context, a compliance platform does not compete with productivity tools w — it competes ith the risk of missing market entry.

That asymmetry is what makes the category attractive for capital: willingness to pay is not driven by perceived value, but by regulatory pressure.

What changes for founders, investors, and corporates

For founders in digital health or medtech, the impact is immediate. Compliance is no longer a resource drain handled internally or outsourced to longcycle consulting firms. It becomes a capability that can be contracted, measured, and scaled. This lowers operational barriers to entry and shortens certification timelines.

For investors and corporates, the reading is more strategic. In regulated sectors, value is not built only in the customerfacing product. It is also built in the operational and regulatory layers that make that product viable.

Investing in this layer is not funding an auxiliary service — it is funding the infrastructure on which the sector’s digital products will be built over the coming years.

This explains why sectorspecialized investors have a real advantage over generalist funds in this category: their ability to assess the technical robustness of regulatory products, not just growth metrics.

More broadly, it reflects a recurring pattern across regulated verticals: value is progressively shifting toward the layers that enable commercialization that deliver it.

The limits that will determine whether this becomes a structural category

The first limit is regulatory dependency. If the European Commission relaxes MDR timelines, the urgency that drives willingness to pay will decrease. MedTech Europe has been actively pushing in that direction. This scenario cannot be ruled out.

The second limit is geographic. MDR is a European regulation, and the addressable market has a different ceiling than the U.S. market under the FDA. Platforms built solely around MDR will need to expand regulatory coverage to justify growthlevel valuations.

The third limit is technical. Automating compliance with AI requires training models on highly specialized documentation, continuously updating them as regulations evolve, and ensuring full traceability in audit environments. The barrier to entry is high — which protects early players, but also increases the cost of building.

Compliance as a product is not a response to a trend. It is a response to a quantifiable market pressure with a defined timeline.

What differentiates platforms with longterm potential from those addressing only the current regulatory moment is their ability to become part of the product development infrastructure.

For a founder, the key question when evaluating these tools is whether they reduce certification costs — or whether they also shorten time to market and integrate into development workflows.

For an investor, the question is whether the platform has value beyond the regulatory deadline that triggered its demand. The ones that do are not selling compliance — they are selling operational efficiency in environments where errors carry real market costs.

Come back to the GCO Ventures blog next month to continue exploring the trends reshaping investment in regulated sectors.